# BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107

### Overview

<b>2024/10/18</b> 08:10:07				
<b>Price</b> <b>7.359</b> EUR				
Difference	0	-4.44% (-0.34)		


General attributes				
ISIN	CA0717341071			
Symbol	ВНС			
Exchange	Duesseldorf			
Currency	EUR			
Sector	Other			
Security type	Stock			
Market cap (m)	2,766 EUR			
Benchmark	S&P/TSX 60 INDEX			

Market data	
Bid (Bid size)	-
Ask (Ask size)	-
Open	7.359 EUR
High	7.359 EUR
Low	7.359 EUR
Close (prev. day)	7.701 EUR
VWAP	-
Volume (pcs)	0
Trading volume	0.00
Number of trades	3
Last size	0

Futures and Options	
Related Futures	14
Related Options	-

### **PDF Downloads**

Company report: BAUSCH HEALTH COMPANIES INC.



Information about previous performance does not guarantee future performance. **Source:** FactSet

### **Recent research**

Ł

on sector			
Date		Headline	Download
2024/09/27	80   120 221   130	Global Equity Ratings	
2024/09/11	6. J.2 21 TS	Global Equity Ratings	
2024/09/05	80   120 221   130	Global Equity Ratings	
2024/08/12	80. L29 271 178	Global Equity Ratings	
2024/07/24	80   28 82   188	Global Equity Ratings	




## **Details**

<b>2024/10/18</b> 08:10	):07	
Price		
<b>7.359</b> EUR		
Difference	0	-4.44% (-0.34)

General attributes				
ISIN	CA0717341071			
Symbol	ВНС			
Exchange	Duesseldorf			
Currency	EUR			
Sector	Other			
Security type	Stock			
Market cap (m)	2,766 EUR			
Benchmark	S&P/TSX 60 INDEX			

Market data	
Bid (Bid size)	-
Ask (Ask size)	-
Open	7.359 EUR
High	7.359 EUR
Low	7.359 EUR
Close (prev. day)	7.701 EUR
VWAP	-
Volume (pcs)	0
Trading volume	0.00
Number of trades	3
Last size	0

Performance and Risk							
	6m 1Y 3Y						
Perf (%)	-8.90%	+0.55%	-69.53%				
Perf (abs.)	-0.72	+0.04	-16.79				
Beta	1.37	1.69	1.77				
Volatility	56.23	48.97	75.75				



Information about previous performance does not guarantee future performance.  $\textbf{Source:} \ \textbf{FactSet}$ 

Price data	
Ø price 5 days   Ø volume 5 days (pcs.)	7.469 EUR (0)
Ø price 30 days   Ø volume 30 days (pcs.)	6.903 EUR (17)
Ø price 100 days   Ø volume 100 days (pcs.)	6.107 EUR (5)
Ø price 250 days   Ø volume 250 days (pcs.)	6.850 EUR (4)
YTD High   date	9.790 EUR (2024/04/02)
YTD Low   date	4.682 EUR (2024/08/08)
52 Weeks High   date	9.790 EUR (2024/04/02)
52 Weeks Low   date	4.682 EUR (2024/08/08)

All listings for BAUSCH HEALTH COMPANIES INC.					
Exchange 🖨	Date	Time	Price	Trading volume (mio.)	Number of trades
Tradegate	2024/10/ 18	22:02	7.516 EUR	0.00	1
Toronto Stock Exchange	2024/10/ 18	22:00	11.26 CAD	2.54	1,057
Stuttgart	2024/10/ 18	21:31	7.492 EUR	0.00	5
SIX Swiss Exchange	2019/06/ 28	17:35	24.11 CHF	0.00	1
NYSE	2024/10/	22:00	8.16 USD	12.08	10,881



	18				
Munich	2024/10/ 18	08:01	7.52 EUR	0.00	2
Frankfurt	2024/10/ 18	08:16	7.361 EUR	0.00	2
Duesseldorf	2024/10/ 18	08:10	7.359 EUR	0.00	3
Berlin	2024/10/ 18	08:01	7.361 EUR	0.00	2



## Company profile

**Company Logo** 

### **BAUSCH** Health

#### **Contact Details**

BAUSCH HEALTH COS. INC.

\_ \_

2150 St. Elzéar Boulevard West - H7L 4A8 Laval

Telefon: +1-514-744-6792

Fax: + E-mail: -

#### **PDF Downloads**

Company report: BAUSCH HEALTH COMPANIES INC.

### **Company Profile**

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Wellibers of Management Board	
Thomas Appio	Chairman of Managing Board
Tage Ramakrishna	Member of Executive Committee
Cees Heiman	Member of Executive Committee
Fernando Zarate	Member of Executive Committee
Graham Jackson	Member of Executive Committee
Jeff Hartness	Member of Executive Committee
Kathleen Fitzpatrick	Member of Executive Committee
Mirza Dautbegovic	Member of Executive Committee

Member of Executive

Member of Executive

Committee

Committee

Seana Carson

Tom Vadaketh

Members of Management Roard

æ,

Board of directors	
John Paulson	Chairman of Supervisory Board
Amy Wechsler	Member of Supervisory Board
Richard Mulligan	Member of Supervisory Board
Brett Icahn	Member of Supervisory Board
Christian Garcia	Member of Supervisory Board
Frank Lee	Member of Supervisory Board
Robert Power	Member of Supervisory Board
Sarah Kavanagh	Member of Supervisory Board
Steven Miller	Member of Supervisory Board

